Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Farletuzumab ecteribulin (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 09 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 28 Oct 2022 Results of exploratory biomarker analysis (n=58) assessing MORAb-202 induced pharmacological effects in patients with ovarian cancer to examine its clinical mechanism of action(MoA), presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
    • 18 Oct 2022 Planned End Date changed from 1 Oct 2022 to 31 Oct 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top